|
1
|
Toiyama Y, Miki C, Inoue Y, Tanaka K,
Mohri Y and Kusunoki M: Evaluation of an inflammation-based
prognostic score for the identification of patients requiring
postoperative adjuvant chemotherapy for stage II colorectal cancer.
Exp Ther Med. 2:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan BH and Fearon KC: Cytokine gene
polymorphisms and susceptibility to cachexia. Curr Opin Support
Palliat Care. 4:243–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan BH, Ross JA, Kaasa S, Skorpen F and
Fearon KC: European Palliative Care Research Collaborative:
Identification of possible genetic polymorphisms involved in cancer
cachexia: A systematic review. J Genet. 90:165–177. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okugawa Y, Miki C, Toiyama Y, Yasuda H,
Yokoe T, Saigusa S, Hiro J, Tanaka K, Inoue Y and Kusunoki M: Loss
of tumoral expression of soluble IL-6 receptor is associated with
disease progression in colorectal cancer. Br J Cancer. 103:787–795.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toiyama Y, Miki C, Inoue Y, Minobe S,
Urano H and Kusunoki M: Loss of tissue expression of interleukin-10
promotes the disease progression of colorectal carcinoma. Surg
Today. 40:46–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Konishi N, Miki C, Yoshida T, Tanaka K,
Toiyama Y and Kusunoki M: Interleukin-1 receptor antagonist
inhibits the expression of vascular endothelial growth factor in
colorectal carcinoma. Oncology. 68:138–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamajima N, Saito T, Matsuo K, Kozaki K,
Takahashi T and Tajima K: Polymerase chain reaction with
confronting two-pair primers for polymorphism genotyping. Jpn J
Cancer Res. 91:865–868. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamajima N, Matsuo K, Saito T, Tajima K,
Okuma K, Yamao K and Tominaga S: Interleukin 1 polymorphisms,
lifestyle factors and Helicobacter pylori infection. Jpn J Cancer
Res. 92:383–389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suma S, Naito M, Wakai K, Sasakabe T,
Hattori Y, Okada R, Kawai S, Hishida A, Morita E, Nakagawa H, et
al: Effects of IL6 C-634G polymorphism on tooth loss and their
interaction with smoking habits. Oral Dis. 21:807–813. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hamajima N, Katsuda N, Matsuo K, Saito T,
Hirose K, Inoue M, Zaki TT, Tajima K and Tominaga S: High
anti-Helicobacter pylori antibody seropositivity associated with
the combination of IL-8-251TT and IL-10-819TT genotypes.
Helicobacter. 8:105–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graziano F, Ruzzo A, Santini D, Humar B,
Tonini G, Catalano V, Berardi R, Pizzagalli F, Arduini F, Bearzi I,
et al: Prognostic role of interleukin-1beta gene and interleukin-1
receptor antagonist gene polymorphisms in patients with advanced
gastric cancer. J Clin Oncol. 23:2339–2345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang D, Zhou Y, Wu L, Wang S, Zheng H, Yu
B and Li J: Association of IL-6 gene polymorphisms with cachexia
susceptibility and survival time of patients with pancreatic
cancer. Ann Clin Lab Sci. 38:113–119. 2008.PubMed/NCBI
|
|
13
|
Carter DB, Deibel MR Jr, Dunn CJ, Tomich
CS, Laborde AL, Slightom JL, Berger AE, Bienkowski MJ, Sun FF,
McEwan RN, et al: Purification, cloning, expression and biological
characterization of an interleukin-1 receptor antagonist protein.
Nature. 344:633–638. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arend WP: Interleukin 1 receptor
antagonist. A new member of the interleukin 1 family. J Clin
Invest. 88:1445–1451. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xue H, Lin B, Ni P, Xu H and Huang G:
Interleukin-1B and interleukin-1 RN polymorphisms and gastric
carcinoma risk: A meta-analysis. J Gastroenterol Hepatol.
25:1604–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fearon KC, Glass DJ and Guttridge DC:
Cancer cachexia: Mediators, signaling and metabolic pathways. Cell
Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Furuta T, El-Omar EM, Xiao F, Shirai N,
Takashima M and Sugimura H: Interleukin 1beta polymorphisms
increase risk of hypochlorhydria and atrophic gastritis and reduce
risk of duodenal ulcer recurrence in Japan. Gastroenterology.
123:92–105. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ferrari SL, Ahn-Luong L, Garnero P,
Humphries SE and Greenspan SL: Two promoter polymorphisms
regulating interleukin-6 gene expression are associated with
circulating levels of C-reactive protein and markers of bone
resorption in postmenopausal women. J Clin Endocrinol Metab.
88:255–259. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hurme M and Santtila S: IL-1 receptor
antagonist (IL-1Ra) plasma levels are co-ordinately regulated by
both IL-1Ra and IL-1beta genes. Eur J Immunol. 28:2598–2602. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vamvakopoulos J, Green C and Metcalfe S:
Genetic control of IL-1beta bioactivity through differential
regulation of the IL-1 receptor antagonist. Eur J Immunol.
32:2988–2996. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vamvakopoulos JE, Taylor CJ, Morris-Stiff
GJ, Green C and Metcalfe S: The interleukin-1 receptor antagonist
gene: A single-copy variant of the intron 2 variable number tandem
repeat (VNTR) polymorphism. Eur J Immunogenet. 29:337–340. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hamajima N, Katsuda N, Matsuo K, Saito T,
Hirose K, Inoue M, Zaki TT, Tajima K and Tominaga S: High
anti-Helicobacter pylori antibody seropositivity associated with
the combination of IL-8-251TT and IL-10-819TT genotypes.
Helicobacter. 8:105–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crawley JB, Williams LM, Mander T, Brennan
FM and Foxwell BM: Interleukin-10 stimulation of
phosphatidylinositol 3-kinase and p70 S6 kinase is required for the
proliferative but not the antiinflammatory effects of the cytokine.
J Biol Chem. 271:16357–16362. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deans DA, Tan BH, Ross JA, Rose-Zerilli M,
Wigmore SJ, Howell WM, Grimble RF and Fearon KC: Cancer cachexia is
associated with the IL10-1082 gene promoter polymorphism in
patients with gastroesophageal malignancy. Am J Clin Nutr.
89:1164–1172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McMillan DC: An inflammation-based
prognostic score and its role in the nutrition-based management of
patients with cancer. Proc Nutr Soc. 67:257–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan BH, Ross JA, Kaasa S, Skorpen F and
Fearon KC: European Palliative Care Research Collaborative:
Identification of possible genetic polymorphisms involved in cancer
cachexia: A systematic review. J Genet. 90:165–177. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan BH, Fladvad T, Braun TP, Vigano A,
Strasser F, Deans DA, Skipworth RJ, Solheim TS, Damaraju S, Ross
JA, et al: P-selectin genotype is associated with the development
of cancer cachexia. EMBO Mol Med. 4:462–471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ries A, Trottenberg P, Elsner F, Stiel S,
Haugen D, Kaasa S and Radbruch L: A systematic review on the role
of fish oil for the treatment of cachexia in advanced cancer: An
EPCRC cachexia guidelines project. Palliat Med. 26:294–304. 2012.
View Article : Google Scholar : PubMed/NCBI
|
